Rossari Biotech Limited — Board Meeting, 27-04-2026: Outcome of Board Meeting

Rossari Biotech's board approved FY26 consolidated results: Revenue ₹2,396.37 Cr, PAT ₹149.21 Cr. A ₹0.50/share final dividend was proposed. Key moves include a new Navi Mumbai R&D facility, re-evaluated capacity expansion, and a ₹19.27 Cr gain from an office sale.